SAILIFE

Sai Life Science Share Price

 

 

Invest in Sai Life Science with 3.26X leverage

Invest with MTF

Performance

  • Low
  • ₹897
  • High
  • ₹915
  • 52 Week Low
  • ₹636
  • 52 Week High
  • ₹943
  • Open Price₹915
  • Previous Close₹910
  • Volume32,991

Investment Returns

  • Over 1 Month + 1.87%
  • Over 3 Month + 1.77%
  • Over 6 Month + 17.85%
  • Over 1 Year + 20.7%

Smart Investing Starts Here Start SIP with Sai Life Science for Steady Growth!

Invest Now

Sai Life Science Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 66.6
  • PEG Ratio
  • 0.5
  • Market Cap Cr
  • 19,069
  • P/B Ratio
  • 8.4
  • Average True Range
  • 23.16
  • EPS
  • 13.56
  • Dividend Yield
  • 0
  • MACD Signal
  • 4.42
  • RSI
  • 56.25
  • MFI
  • 71.27

Sai Life Science Financials

Sai Life Science Technicals

EMA & SMA

Current Price
₹902.75
-7.6 (-0.83%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹893.68
  • 50 Day
  • ₹885.86
  • 100 Day
  • ₹867.27
  • 200 Day
  • ₹816.74

Resistance and Support

905.43 Pivot Speed
  • R3 957.32
  • R2 938.38
  • R1 924.37
  • S1 891.42
  • S2 872.48
  • S3 858.47

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Sai Life Sciences, a leading CRDMO, partners with 280+ global pharma and biotech companies to accelerate NCE small molecule programs. across India, UK, USA, and Japan, it ensures quality and compliance through USFDA-certified facilities.

Sai Life Sciences Ltd has an operating revenue of Rs. 2,053.17 Cr. on a trailing 12-month basis. An annual revenue growth of 16% is outstanding, Pre-tax margin of 13% is healthy, ROE of 7% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 9% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 6% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 99 which is a GREAT score indicating consistency in earnings, a RS Rating of 77 which is FAIR indicating the recent price performance, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 86 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Sai Life Science Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-06 Quarterly Results
2025-08-07 Quarterly Results
2025-05-13 Audited Results
2025-02-06 Quarterly Results

Sai Life Science F&O

Sai Life Science Shareholding Pattern

34.93%
26.16%
3.15%
22.49%
0%
7.91%
5.36%

About Sai Life Science

  • NSE Symbol
  • SAILIFE
  • BSE Symbol
  • 544306
  • Managing Director & CEO
  • Mr. Krishnam Raju Kanumuri
  • ISIN
  • INE570L01029

Similar Stocks to Sai Life Science

Sai Life Science FAQs

Sai Life Science share price is ₹902 As on 31 December, 2025 | 10:33

The Market Cap of Sai Life Science is ₹19068.9 Cr As on 31 December, 2025 | 10:33

The P/E ratio of Sai Life Science is 66.6 As on 31 December, 2025 | 10:33

The PB ratio of Sai Life Science is 8.4 As on 31 December, 2025 | 10:33

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23